BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Molecules 2021;26:1642. [PMID: 33804240 DOI: 10.3390/molecules26061642] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Verhulst E, Garnier D, De Meester I, Bauvois B. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? Cancers (Basel) 2022;14:624. [PMID: 35158891 DOI: 10.3390/cancers14030624] [Reference Citation Analysis]
2 Pirovich DB, Da'dara AA, Skelly PJ. Multifunctional Fructose 1,6-Bisphosphate Aldolase as a Therapeutic Target. Front Mol Biosci 2021;8:719678. [PMID: 34458323 DOI: 10.3389/fmolb.2021.719678] [Reference Citation Analysis]
3 Mokhtar HM, Youssef A, Naguib TM, Magdy AA, Salama SA, Kabel AM, Sabry NM. The Significance of FDG PET/CT–Derived Parameters in Determining Prognosis of Cases with Pancreatic Adenocarcinoma: A Prospective Study. Medicina 2022;58:1027. [DOI: 10.3390/medicina58081027] [Reference Citation Analysis]
4 Heslop KA, Milesi V, Maldonado EN. VDAC Modulation of Cancer Metabolism: Advances and Therapeutic Challenges. Front Physiol 2021;12:742839. [PMID: 34658929 DOI: 10.3389/fphys.2021.742839] [Reference Citation Analysis]